Vigelius-Rauch U, Bräu M
Abteilung Anaesthesiologie, Intensivmedizin, Schmerztherapie, Universiätsklinikum Giessen.
Anasthesiol Intensivmed Notfallmed Schmerzther. 2003 Apr;38(4):321-5. doi: 10.1055/s-2003-38313.
In the last few years global understanding of pain has improved due to current molecular biological studies. The identification of a large number of different proteins is an essential part of future therapies, since they, as enzymes, receptors or ion channels, are specific relays in the nociceptive system and therefore have key functions in pharmacotherapeutic therapy. Nature itself supplies a variety of substances which are of therapeutic value, some of which are already in scientific trial. In contrast, even today not all available pain therapy measures are in use in Germany, at least not in all areas. Especially the treatment of children is not state of the art. Thus a further increase of chronic pain patients is to be expected in the future. This development has to be stopped, not only for ethical reasons, but also to prove the economical value of adequate pain therapy. Qualified treatment of acute pain within well defined limits can help to avoid chronification and further costs. This will be the decisive argument with which to mobilize the necessary funds for the development of the pain treatment of the future.
在过去几年中，由于当前的分子生物学研究，全球对疼痛的认识有所提高。鉴定大量不同的蛋白质是未来治疗的重要组成部分，因为它们作为酶、受体或离子通道，是伤害性感受系统中的特定传导物质，因此在药物治疗中具有关键作用。自然界本身提供了多种具有治疗价值的物质，其中一些已经在进行科学试验。相比之下，即使在今天，德国并非所有可用的疼痛治疗措施都得到应用，至少不是在所有领域。尤其是儿童的治疗并非处于先进水平。因此，预计未来慢性疼痛患者数量会进一步增加。必须阻止这种发展，这不仅出于伦理原因，也是为了证明适当疼痛治疗的经济价值。在明确界定的范围内对急性疼痛进行有资质的治疗有助于避免慢性化和进一步的费用。这将是为未来疼痛治疗的发展筹集必要资金的决定性论据。
